What Inhibrx, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer | May 30 | Disposition to Issuer · D | −59,462 | $30.00 | −$1.78M | 0 |
| Lappe Mark | Chief Executive Officer | May 30 | Disposition to Issuer · D | −500,000 | $30.00 | −$15M | 0 |
| Lappe Mark | Chief Executive Officer | May 30 | Disposition to Issuer · D | −2,486,192 | $30.00 | −$74.6M | 0 |
| Kayyem Jon Faiz | Director | May 30 | Disposition to Issuer · D | −25,000 | $30.00 | −$750K | 0 |
| Kayyem Jon Faiz | Director | May 30 | Disposition to Issuer · D | −25,000 | $30.00 | −$750K | 0 |
| Kayyem Jon Faiz | Director | May 30 | Disposition to Issuer · D | −3,224,301 | $30.00 | −$96.7M | 0 |
| Forsyth Douglas | Director | May 30 | Disposition to Issuer · D | −598,257 | $30.00 | −$17.9M | 0 |
| Viking Global Investors Lp | 10% owner | May 30 | Other Transaction · J | −511,627 | $30.00 | −$15.3M | 0 |
| Viking Global Investors Lp | 10% owner | May 30 | Other Transaction · J | −333,333 | $30.00 | −$10M | 0 |
| Viking Global Investors Lp | 10% owner | May 30 | Other Transaction · J | −6,305,866 | $30.00 | −$189M | 0 |
| Eckelman Brendan P. | Chief Scientific Officer | May 30 | Disposition to Issuer · D | −160,000 | $30.00 | −$4.8M | 0 |
| Eckelman Brendan P. | Chief Scientific Officer | May 30 | Disposition to Issuer · D | −160,000 | $30.00 | −$4.8M | 0 |
| Eckelman Brendan P. | Chief Scientific Officer | May 30 | Disposition to Issuer · D | −1,735,553 | $30.00 | −$52.1M | 0 |
| Eckelman Brendan P. | Chief Scientific Officer | May 28 | Open-market sale · S | −300,000 | $34.30 | −$10.3M | 1,735,553 |
| Viking Global Investors Lp | 10% owner | Aug 28 | Open-market buy · P | +511,627 | $19.35 | +$9.9M | 511,627 |
| Eckelman Brendan P. | Chief Scientific Officer | Mar 01 | Disclosed 10b5-1 sale · S | −400 | $24.71 | −$9.88K | 2,035,553 |
| Eckelman Brendan P. | Chief Scientific Officer | Mar 01 | Disclosed 10b5-1 sale · S | −39,600 | $24.20 | −$958K | 2,035,953 |
| Lappe Mark | Chief Executive Officer | Feb 28 | Disclosed 10b5-1 sale · S | −60 | $25.02 | −$1.5K | 2,486,192 |
| Eckelman Brendan P. | Chief Scientific Officer | Feb 02 | Disclosed 10b5-1 sale · S | −1,130 | $25.89 | −$29.3K | 2,075,553 |
| Eckelman Brendan P. | Chief Scientific Officer | Feb 02 | Disclosed 10b5-1 sale · S | −10,120 | $25.40 | −$257K | 2,076,683 |
Loading...
